FY2024 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Stock analysts at Leerink Partnrs upped their FY2024 EPS estimates for REGENXBIO in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($4.86) per share for the year, up from their prior estimate of ($4.95). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.87) per share. Leerink Partnrs also issued estimates for REGENXBIO’s Q4 2024 earnings at ($1.27) EPS, FY2025 earnings at $0.03 EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($1.74) EPS and FY2028 earnings at ($0.70) EPS.

Several other equities research analysts also recently commented on RGNX. Chardan Capital reiterated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a report on Tuesday. Morgan Stanley restated an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Finally, StockNews.com lowered shares of REGENXBIO from a “hold” rating to a “sell” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.82.

REGENXBIO Trading Down 0.9 %

Shares of RGNX stock opened at $7.88 on Friday. The firm has a market capitalization of $390.38 million, a price-to-earnings ratio of -1.57 and a beta of 1.28. The business’s 50-day moving average price is $8.42 and its 200-day moving average price is $10.38. REGENXBIO has a 12 month low of $6.56 and a 12 month high of $28.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. lifted its holdings in shares of REGENXBIO by 16.8% in the 2nd quarter. American Century Companies Inc. now owns 74,872 shares of the biotechnology company’s stock worth $876,000 after purchasing an additional 10,767 shares in the last quarter. Amalgamated Bank lifted its stake in shares of REGENXBIO by 9.9% in the second quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,227 shares in the last quarter. Hsbc Holdings PLC grew its holdings in shares of REGENXBIO by 37.1% during the second quarter. Hsbc Holdings PLC now owns 19,916 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 5,389 shares during the last quarter. Public Sector Pension Investment Board increased its position in shares of REGENXBIO by 18.7% during the second quarter. Public Sector Pension Investment Board now owns 99,676 shares of the biotechnology company’s stock worth $1,166,000 after acquiring an additional 15,683 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of REGENXBIO during the second quarter worth about $457,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.